These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 18959599)

  • 1. RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes.
    Gribble FM
    Diabet Med; 2008 Aug; 25(8):889-94. PubMed ID: 18959599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
    Yabe D; Seino Y
    Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
    Pathak V; Vasu S; Flatt PR; Irwin N
    Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture.
    Holst JJ
    Diabetes; 2021 Nov; 70(11):2468-2475. PubMed ID: 34711671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
    Kluz J; Adamiec R
    Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic determinants of circulating GIP and GLP-1 concentrations.
    Almgren P; Lindqvist A; Krus U; Hakaste L; Ottosson-Laakso E; Asplund O; Sonestedt E; Prasad RB; Laurila E; Orho-Melander M; Melander O; Tuomi T; Holst JJ; Nilsson PM; Wierup N; Groop L; Ahlqvist E
    JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel extrapancreatic effects of incretin.
    Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin actions beyond the pancreas: lessons from knockout mice.
    Yabe D; Seino Y
    Curr Opin Pharmacol; 2013 Dec; 13(6):946-53. PubMed ID: 24095602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction.
    Fujioka K
    JAAPA; 2007 Dec; Suppl():3-8. PubMed ID: 18217245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based therapy of type 2 diabetes mellitus.
    Knop FK; Vilsbøll T; Holst JJ
    Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating glucose-dependent insulinotropic polypeptide and glucagon as key regulators of insulin secretion in the pancreatic islet.
    Lewandowski SL; El K; Campbell JE
    Am J Physiol Endocrinol Metab; 2024 Jul; 327(1):E103-E110. PubMed ID: 38775725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.
    Gault VA
    Diabet Med; 2018 Jan; 35(1):33-40. PubMed ID: 29044772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
    Ahn CH; Oh TJ; Kwak SH; Cho YM
    Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology of incretins: GLP-1 and GIP.
    Baggio LL; Drucker DJ
    Gastroenterology; 2007 May; 132(6):2131-57. PubMed ID: 17498508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide stimulate release of substance P from TRPV1- and TRPA1-expressing sensory nerves.
    Mayer F; Gunawan AL; Tso P; Aponte GW
    Am J Physiol Gastrointest Liver Physiol; 2020 Jul; 319(1):G23-G35. PubMed ID: 32421358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes.
    Grespan E; Giorgino T; Natali A; Ferrannini E; Mari A
    Metabolism; 2021 Jan; 114():154415. PubMed ID: 33137379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.